INCY vs PAHC: fair value comparison
Incyte Corporation and Phibro Animal Health Corporation · Updated 2026-09-06
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, INCY currently sits closer to the top of our discount ranking. INCY carries the stronger quality grade.
| INCY | PAHC | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $126.75 | $37.15 |
| 12-month range | $93.48–$125.01 | $29.76–$54.68 |
| Sector rank | #37 of 113 Healthcare | #42 of 113 Healthcare |
| Quality grade | A | D |
| Momentum grade | — | A |
| Leverage | Low | High |
| Margin trend | Stable | — |
| Revenue growth | Strong | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Mixed |
| DCF cross-check | Overvalued | — |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: INCY fair value analysis · PAHC fair value analysis